Autor(es): Camargos, Paulo Augusto Moreira ; Ibiapina, C. ; Lasmar, L. ; Cruz Filho, Álvaro Augusto Souza da ; Camargos, Paulo Augusto Moreira ; Ibiapina, C. ; Lasmar, L. ; Cruz Filho, Álvaro Augusto Souza da
Data: 2014
Origem: Oasisbr
Assunto(s): Allergic rhinitis; Asthma; Inhaled corticosteroid
Texto completo: acesso restrito. p. 310–316
Submitted by Suelen Reis (suziy.ellen@gmail.com) on 2014-03-11T12:37:14Z No. of bitstreams: 1 j.1398-9995.2007.01241.x.pdf: 522489 bytes, checksum: 04a9f82545b3668018d7be17881d0d10 (MD5)
Approved for entry into archive by Rodrigo Meirelles (rodrigomei@ufba.br) on 2014-09-09T16:04:21Z (GMT) No. of bitstreams: 1 j.1398-9995.2007.01241.x.pdf: 522489 bytes, checksum: 04a9f82545b3668018d7be17881d0d10 (MD5)
Made available in DSpace on 2014-09-09T16:04:21Z (GMT). No. of bitstreams: 1 j.1398-9995.2007.01241.x.pdf: 522489 bytes, checksum: 04a9f82545b3668018d7be17881d0d10 (MD5) Previous issue date: 2007
Allergic rhinitis (AR) and asthma coexist frequently and a dual treatment is recommended by prescribing topical nasal plus oral inhaled corticosteroids. The purpose of this study was to assess the efficacy of a nasally inhaled corticosteroid aiming at concomitant control of AR and asthma. A controlled trial was conducted among 60 patients with AR and asthma, aged 6–18 years, who were randomized into two groups. During 8 weeks, the experimental group (30 patients) received exclusively fluticasone propionate hydrofluoroalkane (FP-HFA) inhaled through the nose (mouth closed) using a large volume spacer attached to a face mask. The comparison group (30 patients) received a nasal spray of isotonic saline plus oral inhalation of FP-HFA through a mouthpiece attached to the same spacer. Clinical scores for AR and asthma, nasal inspiratory peak flow (NIPF), and spirometry were assessed by blinded observers. There was a significant improvement in AR scores and NIPF in the experimental group (P ≤ 0.01) up to week 8, when a worsening was observed after the intervention was interrupted. Asthma symptoms score, forced expiratory volume (FEV)1, and FEF25−75% were not statistically different between groups at the baseline visit or along follow-up visits (P ≥ 0.20). Prebronchodilator FEV1 (% predicted value) improved by 10% in both groups, comparing values at inclusion with those obtained at the end of follow up. Our results suggest that nasally inhaled FP-HFA through a spacer may control AR and asthma in children and adolescents. This approach is likely to result in higher compliance, lower costs, and fewer side effects.
